pharma · Multiple Myeloma · Ovarian Cancer
pharma&
pharmaand GmbH
pharma& clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Vienna, AT
- Founded
- 2017
- Employees
- 210
- Programs
- 3
- Drugs
- 16
- Patents
- 0
pharma& projects
3 ClinicalTrials.gov programs sponsored by pharma&.
pharma& has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CO-338-087
pharmaand GmbH
Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer
1 trial -
Rucaparib
pharmaand GmbH
Ovarian Cancer
1 trial -
Panobinostat Capsules
pharmaand GmbH
Multiple Myeloma
1 trial
Frequently asked questions
How many clinical projects does pharma& have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.